Bladder Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 56 expanded access programs, clinical trials, and compassionate use pathways listed for Bladder Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with bladder cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 22 programs are currently active or recruiting, with the remaining 34 in other lifecycle stages. Sponsors actively running programs in this area include Merck Sharp & Dohme LLC, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CG Oncology, Inc., Daiichi Sankyo, and others.
By recruiting status
Snapshot of where every Bladder Cancer program currently sits in its lifecycle.
- Active / Recruiting22
- Inactive34
Top sponsors
Organisations running the most Bladder Cancer programs in the directory.
- Merck Sharp & Dohme LLC7 programs
- Memorial Sloan Kettering Cancer Center6 programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5 programs
- CG Oncology, Inc.2 programs
- Daiichi Sankyo2 programs
- Dana-Farber Cancer Institute2 programs
- UroGen Pharma Ltd.2 programs
- AstraZeneca1 program
- Boehringer Ingelheim1 program
- Columbia University1 program
Bladder Cancer programs (56)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- Study on MK-3120 for Treating Bladder Cancer — Merck Sharp & Dohme LLC
- Study on Sacituzumab Tirumotecan (Sac-TMT) for Treating Advanced Urothelial Cancer — Merck Sharp & Dohme LLC
- Phase 3 Study of UGN-102 for Treating Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — UroGen Pharma Ltd.
- Phase II Study of Atezolizumab with Cisplatin and Gemcitabine Before Bladder Cancer Surgery — Memorial Sloan Kettering Cancer Center
- Study on Nivolumab After Chemotherapy and Radiation for Localized Muscle-Invasive Bladder Cancer — University of Utah
- Study on Enfortumab Vedotin and Pembrolizumab with Radiation for Muscle Invasive Bladder Cancer — University of California, San Francisco
- Study on Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab for Treating Localized Muscle-invasive Bladder Cancer — Columbia University
- Study on Intravenous Vitamin C with Gemcitabine and Carboplatin for Muscle Invasive Bladder Cancer — University of Kansas Medical Center
- Study on Gemcitabine and Docetaxel for High-Grade Bladder Cancer Unresponsive to BCG Treatment — Michael A. O'Donnell
- Study on Gemcitabine and Docetaxel for Patients with Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Using Gemcitabine and Docetaxel for Treating Low Grade Intermediate Risk Bladder Cancer — University of Florida
- Study on New Treatments with Enfortumab Vedotin and Pembrolizumab for Urothelial Cancer — Merck Sharp & Dohme LLC
- Study on Nivolumab With and Without Urelumab for Patients Unable to Take Cisplatin or Refusing Chemotherapy with Muscle-Invasive Bladder Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Blue Light Surgery for High-Risk Non-Muscle Invasive Bladder Cancer — Johns Hopkins University
- Study on BCG and N-803 Combination Therapy for Patients with High-Grade Non-Muscle Invasive Bladder Cancer — ImmunityBio, Inc.
- Study on Combining Radiation with Tarlatamab for DLL3 Expressing Tumors — University of Arizona
- Study on Using Pembrolizumab and Enfortumab Vedotin for High Grade Upper Tract Urothelial Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Sacituzumab Govitecan and Enfortumab Vedotin for Treating Advanced Bladder Cancer — Dana-Farber Cancer Institute
- Study on DPX-Survivac with Low Dose Cyclophosphamide and Pembrolizumab for Advanced and Recurrent Solid Tumors — ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Study of CP-383 for Patients with Advanced or Metastatic Solid Tumors — Tasca Therapeutics
- Study Comparing Datopotamab Deruxtecan with Standard Chemotherapy in Advanced Urothelial Cancer — Daiichi Sankyo
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on Pembrolizumab Plus V940 for Bladder Cancer After Surgery — Merck Sharp & Dohme LLC
- Phase 3 Study of UGN-103 for Treating Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — UroGen Pharma Ltd.
- Phase II Study Comparing Chemotherapy Alone to Chemotherapy Plus Durvalumab for Bladder Cancer with Lymph Node Involvement — M.D. Anderson Cancer Center
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — CG Oncology, Inc.
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on Oral Erdafitinib for Recurrent Non-Invasive Bladder Cancer — Memorial Sloan Kettering Cancer Center
- Study of Pemigatinib for Patients with Recurrent Low- or Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Different Radiation Doses for Patients Whose Cancer Progresses on Immunotherapy — Memorial Sloan Kettering Cancer Center
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on TAR-200 with Cetrelimab or Alone Compared to BCG for High-Risk Non-Muscle Invasive Bladder Cancer — Janssen Research & Development, LLC
- Study on the Safety of Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Bladder Cancer Patients Who Cannot Have Chemotherapy — Memorial Sloan Kettering Cancer Center
- Study on Reinduction Treatment with Nadofaragene Firadenovec for Patients with CIS ± High-grade Ta/T1 Bladder Cancer Not Responding to Initial Treatment — Ferring Pharmaceuticals
- Expanded Access Program for Cretostimogene Grenadenorepvec in Treating Bladder Cancer Unresponsive to BCG — CG Oncology, Inc.
- Study on Atezolizumab with Etoposide and Platinum for Small Cell Bladder Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Avelumab and Radiation for Muscle-Invasive Bladder Cancer — Dana-Farber Cancer Institute
- Brightline-2: Testing Brigimadlin (BI 907828) for Cancer in the Biliary Tract, Pancreas, Lung, or Bladder — Boehringer Ingelheim
- Study on Cryoablation with Pembrolizumab or Avelumab for Urothelial Carcinoma — Massachusetts General Hospital
- Study on Enfortumab Vedotin and Radiation for Localized Muscle Invasive Bladder Cancer in Patients Who Cannot Use Cisplatin — University of Texas Southwestern Medical Center
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder — Noah Hahn, M.D.
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] — Memorial Sloan Kettering Cancer Center
- Study Comparing Enfortumab Vedotin and Pembrolizumab with Standard Chemotherapy for Muscle Invasive Bladder Cancer — Merck Sharp & Dohme LLC
- Study on Pembrolizumab with Chemotherapy vs. Placebo with Chemotherapy for Muscle-Invasive Bladder Cancer — Merck Sharp & Dohme LLC
- Phase 2 Study of Pembrolizumab with Gemcitabine and Cisplatin Before Surgery for Muscle-Invasive Bladder Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on RAPA-201 Therapy for Solid Tumors — Rapa Therapeutics LLC
- Study on the Safety and Early Effects of TYRA-300 in Advanced Bladder Cancer and Other Tumors with FGFR3 Gene Changes — Tyra Biosciences, Inc
- Study on the Effectiveness and Safety of Various Immunotherapy Treatments for Urothelial Carcinoma (MORPHEUS-UC) — Hoffmann-La Roche
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study of Cabozantinib and Atezolizumab for Muscle-Invasive Bladder Cancer — Deepak Kilari
- Study on Pembrolizumab and Other Investigational Drugs for High Risk Non-Muscle Invasive Bladder Cancer — Merck Sharp & Dohme LLC
- Study on Tovorafenib (DAY101) Alone or with Other Treatments for Melanoma and Other Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on Ado-Trastuzumab Emtansine for Patients with HER2 Amplified or Mutant Cancers — Memorial Sloan Kettering Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Bladder Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.